45 results about "Human plasma" patented technology

The invention relates to the field of blood products, in particular to a preparation method of human activated C1 esterase. The preparation method comprises the following steps: carrying out contact adsorption on cryoprecipitate-removed human plasma and anion exchange resin, washing and eluting to obtain an eluent containing C1 proesterase, carrying out membrane filtration, and carrying out ultrafiltration desalination treatment; adding an anionic substance into the eluent, incubating in vitro to effectively activate the C1 esterase, and filtering by a membrane to obtain a feed liquid containing the activated C1 esterase; and carrying out purification treatment on the feed liquid to obtain the human activated C1 esterase, and carrying out cryopreservation. According to the method, an anion substance is introduced into an eluent system obtained through anion exchange, mild and effective activation of the C1 proesterase is achieved under the condition of not depending on foreign proteolytic enzyme, the risk of non-specific hydrolysis and self-cutting inactivation is remarkably reduced, good synergy is formed with a follow-up purification process, and the method is suitable for industrial production. The human activated C1 esterase product with relatively high activity and good stability is obtained.

FIELD: pharmacology.SUBSTANCE invention can be used to determine the concentration of an anti-tuberculosis drug in blood serum. The method for determining the concentration of bedaquiline in the blood serum in patients with tuberculosis or mycobacteriosis is that whole blood samples are centrifuged at 3000 rpm for 20 minutes, then the blood plasma is collected in sterile 1.5 mL Eppendorf tubes, then 900 mcL of acetonitrile are added to 300 mcL of plasma and centrifuged at 13500g for 15 minutes, then 1 mL of the supernatant is transferred to a chromatographic vial and make the assay by UHPLC MS / MS using an Athena UHPLC C18, 1.8 mcM, 120A, 2.1×100 mm chromatography column, when using an aqueous solution containing 5 g / L of ammonium acetate, 25 ml / L of concentrated acetic acid, 2 ml / L trifluoroacetic acid as mobile phase A and 100% acetonitrile as mobile phase B, the concentration of bedaquiline is determined using a pre-plotted calibration curve.EFFECT: determination of bedaquiline in human blood plasma in a time not exceeding 6 minutes.1 cl, 9 dwg, 6 tbl

The invention relates to the technical field of pollution treatment equipment, and discloses a syphilis patient plasma pollutant treatment device which comprises a bottom plate, and a mounting frame is fixedly connected to the middle of the top end of the bottom plate; the electromagnetic separation mechanism is arranged in the middle of the top end of the mounting frame and used for separating plasma pollutants of the syphilis patient in an electromagnetic treatment mode; and the regeneration and recovery mechanism is arranged on one side of the top of the mounting frame. By adding and arranging the regeneration and recovery mechanism, when plasma pollutants of syphilis patients are treated, the mechanism can thoroughly recover magnetic nanoparticles in a quartz separation column through flexible switching of conveying of eluent and regeneration liquid through a first three-way solenoid valve, precise liquid supply through combination of a first conveying pump and auxiliary elution through cooperation of an ultrasonic oscillator; and the compound and the particles can be separated through centrifugal treatment of the centrifugal cylinder, the regeneration liquid can enable the particles to be renatured and restore activity, and reutilization is achieved.

The invention relates to a method for measuring the concentration of cefadroxil in K2EDTA human plasma through LC-MS / MS. The method comprises the following steps: preparing a standard curve solution containing cefadroxil d4 by taking K2EDTA human plasma as a matrix, preparing a test solution containing cefadroxil, and precipitating the solution by using acetonitrile; determining the concentration of the test solution containing cefadroxil after precipitation by using an internal standard method; a liquid chromatography tandem mass spectrometer is used for determination, a mobile phase of liquid chromatography is composed of a mobile phase A and a mobile phase B, the mobile phase A is an acetic acid aqueous solution, and the mobile phase B is acetonitrile; the elution procedure of the liquid chromatography is isocratic elution, the volume content of acetonitrile in a mobile phase is 10-30%, and the flow velocity of the mobile phase is 0.4-0.8 mL / min. By optimizing chromatographic conditions and mass spectrum parameters, an efficient and accurate cefadroxil concentration detection method is provided, and the accuracy and reliability of data are ensured.

The present application relates to a kind of HPLC-MS / MS detection method of detecting in human plasma, desloratadine and 3-hydroxydesloratadine in human plasma, it includes the following steps: (1) human plasma sample pretreatment;(2) liquid chromatography-mass spectrometry detection, using mobile phase A and mobile phase B as mixed mobile phase is carried out gradient elution, wherein: mobile phase A is methanol-acetonitrile mixed solution, in mixed solution methanol and acetonitrile volume ratio is 4-6:6-4;Mobile phase B is 2-20mM ammonium formate aqueous solution;(3) the determination of the concentration of human plasma in lopatadine, desloratadine and 3-hydroxydesloratadine.The present application uses lopatadine-d4, desloratadine-d5, 3-hydroxydesloratadine-d4 as deuterium internal standard, using Agilent, ZORBAX Eclipse XDB-Phenyl is carried out gradient elution, deuterium internal standard and the measured substance has the same retention time, chemical property and matrix effect, the reproducibility, accuracy of determining the concentration of lopatadine, desloratadine and 3-hydroxydesloratadine in plasma are good.The method of the present application can be used to evaluate the bioequivalence of lopatadine.

The invention discloses a method for detecting the concentration of Hetrombopag in human plasma through high performance liquid chromatography-tandem mass spectrometry. The method comprises the following steps: adding an internal standard Eltrombopag-13C4 and a precipitator into a plasma sample, uniformly mixing, centrifuging, and taking a supernatant; performing high performance liquid chromatography-tandem mass spectrometry detection on the supernate, and calculating by combining a standard curvilinear equation to obtain the concentration of the Hytrombopag in the human plasma. Through methodology verification of specificity, accuracy, precision, matrix effect, dilution reliability, residue, stability and the like, the detection method can be applied to detection analysis and pharmacokinetic research of a clinical patient hitrombopag plasma sample, so that the use dosage of the medicine is reasonably adjusted, and a safer and more effective individualized medication scheme is provided for the patient.

The invention discloses a high-sensitivity Tau-441 electrochemical immunosensor based on a nano material synergistic amplification effect as well as a preparation method and application of the high-sensitivity Tau-441 electrochemical immunosensor. According to the sensor, a silk-screen printing electrode (SPE) is used as a substrate, a PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode is used as a sensing platform, and electron transfer is promoted by using the large specific surface area and excellent conductivity of the PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode. Meanwhile, gold-modified magnetic nanoparticles (Fe3O4-coated AuNPs) are prepared as a signal probe, and the magnetic separation and enrichment function of Fe3O4 and the biocompatibility and catalytic activity of the gold nanoparticles are combined. The sandwich immune complex is constructed by adopting a homogeneous reaction mode, so that the mass transfer resistance is effectively reduced, and the detection time is shortened. The sensor has an extremely low detection limit (19.68 fgmL <-1 >) and a wide linear range on an Alzheimer's disease marker Tau-441, is high in specificity and good in stability, and is suitable for early-stage rapid screening of human plasma samples.

Inventors describe herein the functional and structural characteristics of the MGL from the anaerobic alkaliphilic thermophile Thermobrachium celere (TcMGL), which was compared to that from Pseudomonas putida (PpMGL). Catalysis was limited to L-Met, L-homocysteine, and L-cysteine, with the highest catalytic efficiency (keat / KM) towards L-Met. The half-life of active TcMGL in human plasma at 37°C was 9.2 hour. Half-life increased from 11.3 hour to 66.7 hour with increasing PLP concentration from 2 to 200 µM, in much greater magnitude than in PpMGL case. TcMGL crystal structure resolution revealed that the enzyme is a tetramer of two catalytic dimers containing a mobile region with open and closed conformations resulting in differences for access to the active site. TcMGL possesses favourable characteristics which makes it a suitable candidate for treatment of cancer. The present invention relates to a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO: 1 or a function-conservative variant thereof.

The invention discloses a method for extracting protein from human plasma for protein analysis, and relates to the technical field of plasma treatment, the key points of the technical scheme are as follows: the method effectively removes high-abundance protein, lipid and other interfering substances in the plasma through two steps of protein precipitation with acetone, degreasing and high-abundance protein removal; the method is suitable for subsequent protein identification and quantitative analysis. A stable and reliable method is provided for pretreatment of the plasma sample, a technical basis is provided for further use of protein in plasma for various medical analyses, and further development of the technology in the plasma detection field is facilitated.

The present application relates to a kind of PLOD2 gene and / or protein as biomarker in the application of preparation auxiliary MASH detection kit.It is also provided that the reagent for detecting the expression amount of PLOD2 in sample is applied to the preparation of auxiliary detection MASH detection kit.The present application finds that the content of PLOD2 in the plasma exosome of patient with metabolic dysfunction-related steatohepatitis is up-regulated, suggesting that the plasma or serum exosome rich in PLOD2 can be used as a new non-invasive biomarker, which can be used for early diagnosis and early treatment of auxiliary MASH patient, and for the progress research and drug research of MASH.

The application relates to a method for quantitatively detecting the concentration of thioctic acid in human plasma by liquid chromatography-tandem mass spectrometry, and belongs to the technical field of biological sample detection. The method comprises the following steps: EDTA-K2 anticoagulant human plasma is taken, thioctic acid-d5 internal standard working solution is added, the mixture is uniformly mixed, acetonitrile is added to precipitate proteins, the supernatant is taken by centrifugation and is diluted; a C18 chromatographic column is used, 0.1% acetic acid aqueous solution and acetonitrile are used as mobile phases for gradient elution; mass spectrometric detection adopts an electrospray ion source negative ion mode and a multiple reaction monitoring mode, the ion pair of thioctic acid is m / z 205.100->171.100, and the ion pair of the internal standard is m / z 210.050->174.100; the peak area ratio is used as a quantitative index, 1 / C 2 weighted linear regression is used to establish a standard curve. The method has the advantages of simple pretreatment, high sensitivity, rapid analysis, strong anti-matrix interference ability, and is suitable for the detection of conventional and hemolytic and hyperlipidemic plasma samples, and can be used for pharmacokinetic research and clinical detection of thioctic acid.

The present application belongs to the technical field of biological detection, and particularly relates to a non-invasive selenium level prediction method based on saliva selenoprotein P detection and application. The present application immunizes mice with heterologously expressed antigen SELENOP (40-194 aa) to generate antibodies, and monoclonal antibodies capable of efficiently recognizing SELENOP are screened and obtained; an ELISA detection method is established using the obtained monoclonal antibodies. The selenium content in human plasma and saliva is detected and analyzed using the detection method and an ICP-MS selenium content detection method, and it is found that there is a significant positive correlation between the three, and a correlation curve between saliva selenoprotein P and human plasma selenium content is established, thereby achieving the purpose of evaluating human selenium level through non-invasive saliva selenoprotein P detection. The technical scheme provided by the present application can be used for large-scale screening and routine health monitoring.

A process is provided for inhibiting or preventing symptoms of necrotizing enterocolitis in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled human plasma derived dimeric and polymeric. When administered in a therapeutic quantity, symptoms of necrotizing enterocolitis in the subject are inhibited or precluded.

The application discloses a methylation marker combination for detecting early esophageal cancer and application thereof. The marker combination comprises 178 methylation sites of 12 specific DNA regions and a specific internal marker region, and the methylation levels of the regions in plasma of patients with early esophageal cancer and healthy people are significantly different. The application also provides a primer combination and a kit for detecting the marker combination, and supports high-throughput deep sequencing. A detection system is used to extract plasma free DNA, perform bisulfite conversion and amplification, calculate a prediction value by using a logistic regression model, multiply the average methylation rate of each region by a corresponding weight coefficient, and compare the result with a threshold value to make a positive judgment. The application greatly improves the detection sensitivity of non-invasive screening for early esophageal cancer under the premise of ensuring high specificity, and has a wide clinical application prospect.

This invention relates to a photoanode material based on a porphyrin covalent organic framework@polyindolepentaformaldehyde, its preparation method, and its application, belonging to the field of photoelectrochemical biosensor technology. This invention uses Dha and Tph to synthesize D-T-COF via a solvothermal method, and modifies it onto the surface of an FTO conductive substrate; further, P5FIn is deposited via electropolymerization to form a uniform and widely distributed layer on the D-T-COF surface. p‑n Heterogeneous junction structure. Based on D-T-COF@P5FIn composite material and p-tau217 capture antibody, an opto-chemical immunosensor array capable of accurately identifying trace amounts of p-tau217 in human plasma was constructed. It has achieved significant breakthroughs in sensitivity, specificity and practicality, and is particularly suitable for the reliable detection of extremely low concentrations of biomarkers in complex biological matrices, showing broad prospects for clinical translational applications.

The application discloses a new type of high-performance liquid chromatography-tandem mass spectrometry analysis method for detecting lanreotide in human plasma, enriches the lanreotide by using a liquid-liquid extraction method, and the quantitative lower limit is 0.05 ng / mL. By liquid-liquid extraction treatment, the interfering substances in human plasma can be removed, and the matrix effect is improved. The solvent composition and pH value of the liquid-liquid extraction are optimized, and the purpose of effective extraction is achieved. The lanreotide standard is used to prepare a standard curve, and the result is corrected by using the lanreotide isotope internal standard, and the detection result has good accuracy. Without additional preparation of antibody reagents, the operation is simple. The method has high sensitivity, specificity and reproducibility, and has many advantages compared with the traditional radioimmunoassay.

The invention relates to the technical field of biomedical analysis, in particular to a clinical steroid hormone determination method which comprises the following steps: repeatedly treating human plasma by adopting a solid-phase extraction method, using octadecylsilane bonded silica gel filler, extracting to remove endogenous steroid hormone, and obtaining a human plasma blank matrix; the method comprises the following steps: respectively preparing a steroid hormone stock solution and a loratadine internal standard solution, taking the human plasma blank matrix treated in the step 1, adding the loratadine internal standard solution, treating with a 2% formic acid solution, extracting by using an HLB solid-phase extraction column, centrifugally concentrating an eluent, redissolving for LC-MS / MS analysis, carrying out sample analysis by adopting an LC-MS / MS method, and determining the content of the loratadine in the human plasma blank matrix. And detecting in an ESI positive ionization mode. Therefore, multiple steroid hormones can be detected at the same time, the coverage concentration range is wide, endogenous interference can be effectively removed, the detection accuracy is improved, the sensitivity is high, the repeatability is good, and the method is suitable for high-throughput analysis of clinical samples.

The present application relates to a kind of HPLC-MS / MS detection method of loxoprofen and its active metabolite trans-OH body in human plasma, it includes the following steps: (1) human plasma sample pretreatment;(2) liquid chromatography-mass spectrometry detection, using mobile phase A and mobile phase B as mixed mobile phase is carried out gradient elution, wherein, mobile phase A is acetonitrile, mobile phase B is 0.05% acetic acid aqueous solution;(3) the determination of loxoprofen and its active metabolite trans-OH body concentration in human plasma.The present application uses ACE, Excel 3SuperC18 as chromatographic column, in the process of gradient elution, the time of optimization elution and the proportion of mobile phase, linear range is all 0.200-40.0ng / mL, lower limit of quantification is low, sensitivity is high, reproducibility, accuracy is all better, can be used to evaluate loxoprofen and its active metabolite trans-OH body each dosage form bioequivalence.

The invention relates to application of a PLOD2 gene and / or protein as a biomarker in preparation of an auxiliary MASH detection kit. The invention further provides application of the reagent for detecting the expression quantity of the PLOD2 in the sample in preparation of a detection kit for assisting in detecting MASH. The invention finds that the PLOD2 content in the plasma exosome of the patient with metabolic dysfunction related steatohepatitis is up-regulated, which prompts that the plasma or serum exosome rich in PLOD2 can be used as a new non-invasive biomarker, can be used for assisting the early diagnosis and early treatment of the MASH patient, and can be used for the disease progress research and drug research of MASH.

The invention discloses a method for detecting the concentration of carbamatinib in human plasma, and belongs to the technical field of drug analysis and detection. Preparing standard curve working solutions of carbamatinib with different concentrations, diluting with blank plasma, and carrying out precipitation reaction to prepare standard curve sample solutions with a series of concentrations; the method comprises the following steps: mixing to-be-detected plasma and a carbamatinib-13C-d3 internal standard solution to perform precipitation reaction, performing centrifugal separation, taking supernate, and adding an acetonitrile aqueous solution containing 0.1% formic acid into the supernate to dilute the supernate as a test solution; carrying out liquid chromatography-mass spectrometry detection on the standard curve sample solution with a series of concentrations and the test sample solution, and calculating the content of the carbamatinib in the blood plasma through a standard curve by using an internal standard method; the method has the advantages of high sensitivity, accuracy, reliability, good selectivity, small matrix effect, rapidness, simplicity, convenience and the like. The method is suitable for the blood concentration detection and pharmacokinetic research of the carbamatinib, and provides a basis for the consistency evaluation of the carbamatinib preparation.

Provided herein are compositions comprising allogeneic human plasma and platelet derived product, and methods for making the compositions and using the compositions as a therapeutic for example, in orthopedic indications.

The invention provides a method of manufacturing an IgM-containing composition depleted of anti-A and / or anti-B immunoglobulin from human plasma. An IgM-containing composition derived from human plasma having 5% or more IgM of the total immunoglobulin is contacted with a macroporous chromatography resin coupled with a ligand comprising GalNAcα1-3(Fucα1-2)Galβ1-4Glc- and / or Galα1-3(Fucα1-2)Galβ1-4Glc-. The flow-through is recovered.

This invention relates to the field of pharmaceutical analysis technology, specifically to a method for determining the concentration of the antihypertensive drug losartan in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS / MS). The mobile phase of the LC comprises an aqueous formic acid solution and acetonitrile; the elution program of the LC includes: 60-80% acetonitrile by volume in the mobile phase for 0-1.4 min; and a flow rate of 0.6-1 mL / min. This invention provides a highly efficient and accurate method for detecting losartan drug concentration, enabling precise determination of the losartan concentration in plasma and ensuring the accuracy and reliability of the data.

The invention belongs to the field of medicine biological analysis, and particularly relates to a detection method for determining the concentration of dioscin in human plasma. The method is a liquid chromatography-tandem mass spectrometry method, and the liquid chromatography adopts the following conditions: a chromatographic column: ACQUITYHSS T3, 1.8 [mu] m, 2.1 * 75 mm, a monitor: MS / MS, a mobile phase A: 0.1 mM ammonium acetate, a mobile phase B: acetonitrile, and the elution gradient is as follows. According to the liquid chromatography-tandem mass spectrometry method, the separation and the detection of the dioscin are realized through an ultrahigh-phase liquid phase mass spectrometer. The detection method provided by the invention is the only disclosed method for detecting the blood concentration of dioscin in human plasma at present, and can be used for supporting non-clinical and clinical research work of the medicine.

Provided herein are settable and non-settable compositions for use in surgical procedures comprising a variety of disclosed particles and optionally including previously unclotted, lyophilized, optionally crosslinked mammalian blood plasma. Also provided are related compositions, including surgical kits and packages, as well as methods of making and using the compositions.

The invention relates to a hepatitis A virus (HAV) fusion protein as well as a preparation method and application thereof, prokaryotic expression and purification are carried out based on connection and fusion of main antigen regions of HAV capsid proteins VP1 and VP3, a high-purity HAV-rVP13 fusion protein is obtained, the HAV-rVP13 fusion protein is used as a coating antigen, and an ELISA detection method for an HAV specific IgG antibody is established. By establishing an enterprise calibrator and a quality control product and calibrating by a national HAV specific IgG standard product, the established ELISA detection method can quantitatively determine the concentration of the HAV specific IgG antibody in human plasma / serum, has very high sensitivity and specificity, and can be used for quantitative detection of the HAV IgG antibody in a human plasma / serum sample.

The present invention relates to a method for monitoring a parameter in a solution or suspension and to the use of said method in a method for purifying a solution comprising human plasma proteins and other components. In one aspect, the invention provides a method for determining a concentration of an analyte in a sample obtained from a blood-derived plasma treatment, the method comprising: applying a light source to a test sample obtained from a blood-derived plasma treatment; measuring inelastic scattering or Raman shift from the test sample, thereby generating a test spectrum and a predictive model; the test spectrum is compared to a reference spectrum obtained from a reference sample having a known concentration of the analyte to determine the concentration of the analyte in the sample.

The invention provides a method for detecting atavalopag in human plasma by HPLC-MS / MS (High Performance Liquid Chromatography-Mass Spectrometry / Mass Spectrometry). The method comprises the following steps: (1) pretreating a human plasma sample; (2) carrying out liquid chromatography-mass spectrometry detection; a mobile phase A and a mobile phase B are adopted as mixed mobile phases for gradient elution, and the mobile phase A is a methanol-acetonitrile mixed solution; a mobile phase B is a 2-20 mM ammonium acetate aqueous solution; and (3) determining the atavalopag in the human plasma. According to the method, ZORBAX SB-C18 is adopted as a chromatographic column, a specific mobile phase is screened out, the proportion and time of the mobile phase in the gradient elution process are optimized, and the method has the advantages of being good in reproducibility, high in sensitivity, high in analysis speed, small in matrix effect influence, high in recovery rate and the like.

The invention discloses a composition for detecting methylation of a human plasma SOX15 gene and an EME1 gene for lung cancer, which can be used for realizing early screening and early diagnosis of the lung cancer through detection of plasma DNA (Deoxyribonucleic Acid). Meanwhile, the invention further provides a kit for methylation of the SOX15 gene and the EME1 gene, the sensitivity of detection of lung cancer patients reaches 83.49%, and the specificity is 92.10%.